Adjuvant chemotherapy of lung cancer: Methodologic issues and therapeutic advances

Hematology/Oncology Clinics of North America

Volumn 19, Issue 2, 2005, Pages 263-281

  Strauss, Gary M ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BCG VACCINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LEVAMISOLE; LOMUSTINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; UFT; VINBLASTINE; VINCRISTINE; VINDESINE;

ANOREXIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; EPIDEMIOLOGICAL DATA; EXPERIMENT; FEBRILE NEUTROPENIA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LETHARGY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS; NEUTROPENIA; PATHOLOGICAL ANATOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; TOXICITY; TREATMENT OUTCOME; TUMOR VOLUME; VALIDATION PROCESS;

EID: 17044393041     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.02.008     Document Type: Review

References (66)

1. D. Parkin Global cancer statistics in the year 2000 Lancet Oncol 2 2001 533 543
2. A. Jemal, R. Tiwari, and T. Murray Cancer statistics-2004 CA Cancer J Clin 54 2004 8 29
3. C.F. Mountain A new International Staging System for lung cancer Chest 89 1986 225S 233S
4. W.A. Fry, J.L. Phillips, and H.R. Menck Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report Cancer 86 1999 1867 1876
5. C.E. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
6. C.F. Mountain, and C.M. Dresler Regional lymph node classification for lung cancer staging Chest 111 1997 1718 1723
7. G.M. Strauss, and R. Rathore Lung cancer J.D. Crapo J. Glassroth J.B. Karlinsky Baum's textbook of pulmonary diseases 2004 Lippincott Williams & Wilkins Philadelphia 787 857
8. J. Wisnivesky, D. Yankelevitz, and C. Henschke The effect of tumor size on curability of stage I non-small cell lung cancers Chest 126 2004 761 765
9. N. Martini, M. Burt, and M. Bains Survival after resection of stage II non-small cell lung cancer Ann Thorac Surg 54 1992 460 466
10. F. Detterbeck, and T. Egan Surgery for stage II non-small cell lung cancer F. Detterbeck M. Rivera M. Socinski Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing physician 2001 WB Saunders Company Philadelphia 177 190
11. E.C. Holmes Treatment of stage II lung cancer (T1N1, T2N1) Surg Clin N Am 67 1987 945 949
12. R.J. Ginsberg, M. Goldberg, and P.F. Waters Surgery for non-small cell lung cancer J. Roth J. Ruckdeschel T.H. Weisenburger Thoracic oncology 1989 W.B. Saunders Co. Philadelphia 177 199
13. F. Detterbeck, and T. Egan Surgical treatment of stage IIIA (N2) non-small cell lung cancer F. Detterbeck M. Rivera M. Socinski Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing physician 2001 WB Saunders Company Philadelphia 244 256
14. F. Pearson, N. Delarue, and R. Ives Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung J Thorac Cardiovasc Surg 83 1982 1 11
15. N. Martini, and B.J. Flehinger The role of surgery in N2 lung cancer Surg Clin N Am 67 1987 1037 1049
16. E.C. Holmes, M. Gail The Lung Cancer Study Group Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma J Clin Oncol 4 1986 710 715
17. R. Feld, L. Rubinstein, and P.A. Thomas Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer J Natl Cancer Inst 85 1993 299 306
18. A. Niranen, S. Niitamo-Korhonen, and M. Kouri Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study J Clin Oncol 10 1992 1927 1932
19. T. Lad, L. Rubinstein, A. Sadeghi The Lung Cancer Study Group The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer J Clin Oncol 6 1988 9 17
20. B. Dautzenberg, C. Chastang, and R. Arriagada Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected non-small cell lung carcinoma Cancer 76 1995 779 786
21. S.M. Keller, S. Adak, and H. Wagner A randomized trial of postoperative adjuvant therapy in patient with completely resected stage II or IIIa non-small cell lung cancer N Engl J Med 343 2000 1217 1222
22. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials BMJ 311 1995 899 911
23. S. Yusuf, R. Collins, and R. Peto Why do we need large, simple randomized trials? Stat Med 3 1984 409 420
24. R. Collins, R. Peto, and R. Gray Large scale randomized evidence: trials and overviews D. Warrel T. Cox J. Firth Oxford textbook of medicine 2003 Oxford University Press Oxford (UK) 24 36
25. D.B. Petitti Statistical methods in meta-analysis Meta-analysis, decision analysis, and cost effectiveness 2000 Oxford University Press Oxford (UK) 94 118
26. Early Breast Cancer Trialists Collaborative Group Tamoxifen for early breast cancer: an overview of randomized trials Lancet 351 1998 1451 1467
27. Writing Committee for the IALT R. Arriagada, and B. Bergman Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: The International Adjuvant Lung Cancer Trial (IALT) Collaborative Group N Engl J Med 350 2004 351 360
28. N. Ikhlaque, and M. Baumann Adjuvant chemotherapy for lung cancer [correspondence] N Engl J Med 350 2004 1681
29. A. Buyukcelik, G. Utkan, and B. Yalcin Adjuvant chemotherapy for lung cancer [correspondence] N Engl J Med 350 2004 1681
30. A. Dunant, J.P. Pignon, and T. Le Chevalier Adjuvant chemotherapy for lung cancer [correspondence: the authors' reply] N Engl J Med 350 2004 1682 1683
31. S. Greenland, and K.J. Rothman Introduction to stratified analysis K.J. Rothman S. Greenland Modern epidemiology 1998 Lippincott-Raven Publishers Philadelphia 253 279
32. S. Greenland, and K.J. Rothman Concepts of interaction K.J. Rothman S. Greenland Modern epidemiology 1998 Lippincott-Raven Publishers Philadelphia 329 342
33. G. Scagliotti, R. Fossati, and V. Torri Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer J Natl Cancer Inst 95 2003 1453 1461
34. D. Waller, D. Fairlamb, and N. Gower The Big Lung Trial: determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting [abstract] Proc Am Soc Clin Oncol 22 2003 632
35. D.P. Harrington The randomized clinical trial A.E. Raftery M.A. Tanner M.T. Wells Statistics in the 21st century 2002 American Statistical Association - Chapman & Hall/CRC Alexandria (VA) 67 74
36. B. Fisher, P. Carbone, and S. Economou 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings N Engl J Med 292 1975 117 122
37. G. Bonadonna, E. Brusamolino, and P. Valagussa Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 1976 405 410
38. G. Tancini, G. Bonadonna, and P. Valagussa Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles J Clin Oncol 1 1983 2 10
39. B. Fisher, A. Brown, and N. Dimitrov Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 8 1990 1483 1496
40. P. Eifel, J. Axelson, and J. Costa National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000 J Natl Cancer Inst 93 2001 979 989
41. I. Henderson, D. Berry, and G. Demetri Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 2003 976 983
42. M. Citron, D. Berry, and C. Cirrincione Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439
43. B. Fisher, J. Dignan, and A. DeCillis The worth of chemotherapy and tamoxifen over tamoxifen alone in node-negative patients with estrogen-receptor positive breast cancer: first results from the NSABP B-20 [abstract] Proc Am Soc Clin Oncol 16 1997 1a
44. B. Fisher, S. Anderson, and E. Tan-Chiu Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 J Clin Oncol 19 2001 931 942
45. Early Breast Cancer Trialists Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1992 1 15
46. Early Breast Cancer Trialists Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1992 71 85
47. Early Breast Cancer Trialists Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 1998 930 942
48. R. Diasio Adjuvant chemotherapy for adenocarcinoma of the lung-is the standard of care ready for change? N Engl J Med 350 2004 1777 1779
49. N. Keicho, N. Saijo, and T. Shinkai Phase II study of UFT in patients with advanced non-small cell lung cancer Jpn J Clin Oncol 16 1986 143 146
50. E. Shimizu, K. Kimura, and S. Sone A phase II study of UFT in non-small cell lung cancer Jpn J Cancer Chemother 13 1986 2970 2973
51. F. Tanaka, H. Wada, and M. Fukushima Antiangiogenic effect of UFT and its clinical significance in postoperative adjuvant therapy for NSCLC Proc Am Soc Clin Oncol 21 2002 213b
52. H. Wada, S. Hitami, T. Teramatsu West Japan Study Group for Lung Cancer Surgery Adjuvant chemotherapy after complete resection in non-small cell lung cancer J Clin Oncol 14 1996 1048 1054
53. H. Kato, Y. Ichinose, and M. Ohta A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 2004 1713 1721
54. M. Nakagawa, F. Tanaka, and N. Tsubota A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study Ann Oncol 16 2005 75 80
55. T. Winton, R. Livingston, and D. Johnson A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non-small cell lung cancer: Intergroup JBR 10 J Clin Oncol-Proc Am Soc Clin Oncol 22 Suppl 14S 2004 621S
56. F. Shepherd, T. Winton, and R. Livingston The impact of adjuvant vinorelbine and cisplatin on quality of life: results from the National Cancer Institute of Canada Clinical Trials Group Trial BR.10 randomized trial of vindesine/cisplatin versus observation in stage IB and II non-small cell lung cancer Ann Oncol 15 Suppl 3 2004 iii165
57. G.M. Strauss, J.E. Herndon, and M.A. Maddaus Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 J Clin Oncol-Proc Am Soc Clin Oncol 22 Suppl 14S 2004 621a
58. A. Sedrakyan, J. van Der Meulen, and K. O'Byrne Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis J Thorac Cardiovasc Surg 128 2004 414 419
59. K. Hotta, K. Matsuo, and H. Ueoka Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials J Clin Oncol 22 2004 3860 3867
60. M. Zelen Theory and practice of clinical trials J.E. Holland R.C. Bast D.L. Morton Cancer medicine 2000 BC Decker Inc. Baltimore (MD) 298 313
61. S. Borzak, and P. Ridker Discordance between meta-analyses and large-scale randomized, controlled trials Ann Intern Med 123 1995 873 877
62. A.R. Feinstein Meta-analysis: statistical alchemy for the 21st century J Clin Epidemiol 48 1995 71 79
63. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
64. J. Pogue, and S. Yusuf Overcoming the limitations of current meta-analysis of randomized controlled trials Lancet 351 1998 47 52
65. M. Ohta, R. Tsuchiya, and M. Shimoyama Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study J Thorac Cardiovasc Surg 106 1993 703 708
66. R. Blum Adjuvant chemotherapy for lung cancer -a new standard of care N Engl J Med 350 2004 404 405